The maker of Ozempic and Wegovy found fake 1-milligram injections were being distributed through unauthorized sellers.

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.86) for a 5 milligram ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.